Anika Therapeutics Inc (ANIK)

R&D Expense Growth

9.35%

Quarterly · Period ending:

ANIK logo

ANIK R&D Expense Growth

Latest reported9.35%
ANIK Quarterly R&D Growth (QoQ) (0.00% → 9.35%)
High-resolution chart · PNG

ANIK r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Anika Therapeutics Inc R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
9.355%
4.0453%
-7.112%
10.0269%
4.1921%
121.2929%
-62.2032%
8.4107%
-18.1529%
7.6335%
-2.6441%
-12.5982%
6.119%
8.4011%
6.1361%
4.6738%
13.2857%
2.6167%
-21.8037%
5.2105%
14.6518%
-16.6536%
46.291%
15.1147%
-25.0909%
48.1391%
-1.7797%
-0.1681%
-2.1841%
4.7736%
-3.9698%
-10.5853%
-8.293%
20.9798%
-26.9771%
31.3104%
5.1773%
42.9537%
4.8547%
1.0745%
29.3191%
-28.4151%
46.2878%
13.7597%
-13.607%
5.7653%
-0.8228%
6.7645%
-18.121%
12.7008%
25.4565%
-11.5382%
15.55%
18.1561%
10.0725%
-6.246%
-15.324%
0.1529%
-0.0387%
-2.7189%
2.7071%
10.4453%
-21.8024%
-3.3773%
-2.0788%
42.2183%
-44.6361%
4.1954%
4.1891%
-10.236%
35.6895%
9.5428%
9.035%
8.0936%
23.9447%
13.029%
17.5502%
67.9642%
-44.2745%
-19.8772%
4.9299%
-1.4829%
11.6445%
-32.9911%
21.8515%
12.3711%
7.996%
-12.1778%
24.0353%
38.2622%
36.0996%
-25.6173%
-19.9011%
2.6268%
-21.1026%
-4.8827%
-3.6195%
-8.0234%
43.3904%
-10.3055%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.